reference/3317728

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/3317728

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Multicenter Study\|Randomized Controlled Trial
endingPage	74
issn	0925-5710 1865-3774
issueIdentifier	1
pageRange	65-74
publicationName	International Journal of Hematology
startingPage	65
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_06eaa1e0712a06307c6b4a669fb6f18c
bibliographicCitation	Kubo K, Hori M, Ohta K, Handa H, Hatake K, Matsumoto M, Hagiwara S, Ohashi K, Nakaseko C, Suzuki K, Ito S, Kinoshita G, Shelat SG, Miyoshi M, Takezako N. Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan. International Journal of Hematology. 2019 Nov 07;111(1):65–74. doi: 10.1007/s12185-019-02757-0.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_90cafa602a0af4589db1f5db7f150dda http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9b347f2e56c18721f306374c2a3071bc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5814fa1358728c51ea8d3badcfe266d4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3e6c9414cf82bbcef94ffd9f96b128d5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a3d1b3aacc7f066feb49a93cef206197 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_512f4fdaa752985620f5987252bbe311 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5c3d885f73a34dfb69db7a8eabc21f26 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0f970329f11724ca282d5e85f03bd504 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d879ff512929cd1606d71c90f1074534 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_38345375039d028f08a4ac71341f83b1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_71ea5b25adb2cf83143b96c90bc25ffd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9cb723ef4788bf2293c56b8ce4a1824b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cf453be36625ad19caa3d2a31c174194 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1b88e244722cdb4438acea26aea5c108 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c029931212bc6d7cf4eaaca31244be67
date	2019-11-07^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/31701481 https://doi.org/10.1007/s12185-019-02757-0
isPartOf	https://portal.issn.org/resource/ISSN/0925-5710 https://portal.issn.org/resource/ISSN/1865-3774 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1221
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://scigraph.springernature.com/ https://www.crossref.org/
title	Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan
discusses	http://id.nlm.nih.gov/mesh/M0006099 http://id.nlm.nih.gov/mesh/M0542262 http://id.nlm.nih.gov/mesh/M0556300 http://id.nlm.nih.gov/mesh/M0479831
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D009101Q000188 http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D000077269Q000008 http://id.nlm.nih.gov/mesh/D003907Q000008 http://id.nlm.nih.gov/mesh/D061067Q000008
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D033581 http://id.nlm.nih.gov/mesh/D000077982 http://id.nlm.nih.gov/mesh/D007564 http://id.nlm.nih.gov/mesh/D009101Q000473 http://id.nlm.nih.gov/mesh/D009101Q000378 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D003907Q000009 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D061067Q000009 http://id.nlm.nih.gov/mesh/D000971Q000009 http://id.nlm.nih.gov/mesh/D000077269Q000009 http://id.nlm.nih.gov/mesh/D004334
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8530 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5743 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID216326

Showing number of triples: 1 to 65 of 65.